<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02698839</url>
  </required_header>
  <id_info>
    <org_study_id>PIONEER-II, RCT, P01</org_study_id>
    <nct_id>NCT02698839</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)</brief_title>
  <acronym>RCT</acronym>
  <official_title>A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients With de Novo Coronary Lesions, RCT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sino Medical Sciences Technology Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sino Medical Sciences Technology Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PIONEER-II RCT trial is a prospective, multicenter, randomized, non-inferiority registry&#xD;
      trial. 539 subjects from about 40 interventional cardiology centers in China will be enrolled&#xD;
      to evaluate In-stent late lumen loss(LLL) as the primary endpoint at 9 months. And all the&#xD;
      subjects will be followed up to 5 years to attain the data of the secondary endpoints.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Realizing even more uniform and complete endothelial coverage, BuMA Supreme™ biodegradable&#xD;
      drug coating coronary stent system comprises a new generation of biodegradable drug eluting&#xD;
      stent under development by SINOMED. BuMA Supreme™ reconfigures BuMA™ DES utilizing a high&#xD;
      caliber cobalt chromium platform coated with rapidly degrading PLGA scaffold.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>in-stent Late Lumen Loss, 9M</measure>
    <time_frame>QCA at 9-month follow-up window</time_frame>
    <description>The primary endpoint is in-stent Late Lumen Loss (LLL) at 9-month after stent implantation as assessed by off-line quantitative coronary angiography (QCA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent implantation success rate</measure>
    <time_frame>5 years after PCI</time_frame>
    <description>The stent implantation success rate includes device success, lesion success and clinical success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis rate</measure>
    <time_frame>9 months</time_frame>
    <description>Binary restenosis was defined in every segment (proximal, distal, and stent) as a &gt;50% diameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in-segment LLL</measure>
    <time_frame>9 months</time_frame>
    <description>to evaluate the in-sigment Late Lumen Loss (LLL) at 9-month after stent implantation as assessed by off-line quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diameter stenosis degree</measure>
    <time_frame>9 months</time_frame>
    <description>to compare the lumen diameter at 9-month after stent implantation with the baseline diameter as assessed by off-line quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-oriented Composite Endpoint (DoCE)</measure>
    <time_frame>1, 6, 12 month, and annually up to 5 years post procedure</time_frame>
    <description>Device-oriented Composite Endpoint is defined as cardiac death, target vessel MI, or clinically-driven target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented Composite Endpoint (PoCE)</measure>
    <time_frame>1, 6, 12 month, and annually up to 5 years post procedure</time_frame>
    <description>Patient-oriented Composite Endpoint is defined as all cause death, all myocardial ischemia (MI), or any revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Academic Research Consortium(ARC) defined stent thrombosis</measure>
    <time_frame>5 years after PCI</time_frame>
    <description>Definite and probable stent thrombosis during acute, subacute, later and very late phase.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">539</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>BuMA Supreme group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group contains 319 subjects. Among them, 220 subjects will be implanted with regular specifications and 99 subjects with narrower, wider or longer ones.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BuMA™ group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group contains 220 subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BuMA Supreme</intervention_name>
    <description>Stent platform: cobalt-chromium alloy</description>
    <arm_group_label>BuMA Supreme group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BuMA™</intervention_name>
    <description>Stent platform: stainless steel</description>
    <arm_group_label>BuMA™ group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-75, male or non-pregnant female&#xD;
&#xD;
          2. Evidence of non-symptomatic ischemia, stable or non-stable angina pectoris or past MI&#xD;
&#xD;
          3. Target lesion is primary and de-novo coronary artery disease&#xD;
&#xD;
          4. The target lesion length ≤ 60 mm, diameter 2.25mm-5.0mm (visually estimated)&#xD;
&#xD;
          5. Lesion diameter stenosis ≥70% (visually estimated)&#xD;
&#xD;
          6. For each target lesion, same stent implantation only&#xD;
&#xD;
          7. Acceptable candidate for coronary artery bypass grafting (CABG)&#xD;
&#xD;
          8. Understand the study purpose, willing to participate and sign the letter of consent,&#xD;
             agrees to the follow-up visits including a 9 month angiographic follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute MI within 1 week&#xD;
&#xD;
          2. Chronic total occlusion(TIMI 0), left main lesion, intervention-required three-vessel&#xD;
             lesions, branch vessel diameter ≥ 2.5mm and bypass lesion&#xD;
&#xD;
          3. More than 3 stents required&#xD;
&#xD;
          4. Patients refuse to be implanted stent&#xD;
&#xD;
          5. Calcified lesion failed in pre-dilation, twisted lesion and lesion unsuitable for&#xD;
             stent delivery and expansion&#xD;
&#xD;
          6. In-stent restenosis&#xD;
&#xD;
          7. Planned percutaneous coronary intervention (PCI) within 3 months post procedure&#xD;
&#xD;
          8. Other stents implanted within 1 year&#xD;
&#xD;
          9. Severe heart failure (NYHA above III) or left ventricle ejection fraction (EF) &lt;40%&#xD;
&#xD;
         10. Renal function damage, blood creatinine &gt; 176.82 μmol/L&#xD;
&#xD;
         11. Bleeding tendency, active peptic ulcer disease, cerebral or subarachnoid hemorrhage,&#xD;
             cerebral apoplexy within half year and contraindication for any anti-platelet or&#xD;
             anticoagulation agents&#xD;
&#xD;
         12. Allergic to drugs or agents used in stent or protocol (PLGA, sirolimus, aspirin,&#xD;
             clopidogrel, contrast agent, cobalt, nickel, chromium, iron, wolfram et. al.)&#xD;
&#xD;
         13. Life expectation &lt; 12 months&#xD;
&#xD;
         14. Have not reached the primary end point when participating in other trial&#xD;
&#xD;
         15. Poor compliance to the protocol&#xD;
&#xD;
         16. Heart implantation cases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yundai Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shubin Qiao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shaoping Nie, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yawei Xu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai 10th People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiangqing Kong, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Jiangsu Proving Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lang Li, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital of Guangxi Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiangqian Shen, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Central South University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hui Li, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Daqing oilfield general hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linghong Shen, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xi Su, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Wuhan Asia Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiyan Chen, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Guangdong Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Genshang Ma, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Zhongda Hospital Southeast University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaoshu Cheng, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Second Affiliated Hospital of Nanchang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guosheng Fu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Run Run Shaw Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zesheng Xu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Cangzhou Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianan Wang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The Second Affiliated Hospital of Zhejiang University School of Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haichu Yu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The Affiliated Hospital of Qingdao University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guotai Sheng, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Jiangxi Provincial People's Hopital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiandong Li, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Shengjing Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tingbo Jiang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kui Chen, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hua Wang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Menghong Wang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Nanchang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Honghua Ye, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Hua Mei Hospital, University of Chinese Academy of Sciences(Ningbo No.2 Hospital)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guohai Su, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Jinan Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manhua Chen, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Wuhan Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yongjun Li, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The Second Hospital of Hebei Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2016</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug eluting stents</keyword>
  <keyword>Interventional Cardiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

